Stock Research for EPZM

EPZM

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

EPZM Stock Chart & Research Data

The EPZM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the EPZM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


EPZM Due diligence Resources & Stock Charts

The EPZM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View EPZM Detailed Price Forecast - CNN Money CNN View EPZM Detailed Summary - Google Finance
Yahoo View EPZM Detailed Summary - Yahoo! Finance Zacks View EPZM Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View EPZM Trends & Analysis - Trade-Ideas Barrons View EPZM Major Holders - Barrons
NASDAQ View EPZM Call Transcripts - NASDAQ Seeking View EPZM Breaking News & Analysis - Seeking Alpha
Spotlight View EPZM Annual Report - CompanySpotlight.com OTC Report View EPZM OTC Short Report - OTCShortReport.com
TradeKing View EPZM Fundamentals - TradeKing Charts View EPZM SEC Filings - Bar Chart
WSJ View Historical Prices for EPZM - The WSJ Morningstar View Performance/Total Return for EPZM - Morningstar
MarketWatch View the Analyst Estimates for EPZM - MarketWatch CNBC View the Earnings History for EPZM - CNBC
StockMarketWatch View the EPZM Earnings - StockMarketWatch MacroAxis View EPZM Buy or Sell Recommendations - MacroAxis
Bullish View the EPZM Bullish Patterns - American Bulls Short Pains View EPZM Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View EPZM Stock Mentions - StockTwits PennyStocks View EPZM Stock Mentions - PennyStockTweets
Twitter View EPZM Stock Mentions - Twitter Invest Hub View EPZM Investment Forum News - Investor Hub
Yahoo View EPZM Stock Mentions - Yahoo! Message Board Seeking Alpha View EPZM Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for EPZM - SECform4.com Insider Cow View Insider Transactions for EPZM - Insider Cow
CNBC View EPZM Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for EPZM - OTC Markets
Yahoo View Insider Transactions for EPZM - Yahoo! Finance NASDAQ View Institutional Holdings for EPZM - NASDAQ


Stock Charts

FinViz View EPZM Stock Insight & Charts - FinViz.com StockCharts View EPZM Investment Charts - StockCharts.com
BarChart View EPZM Stock Overview & Charts - BarChart Trading View View EPZM User Generated Charts - Trading View




Latest Financial News for EPZM


Epizyme to Participate in Upcoming Investor Conferences
Posted on Wednesday August 29, 2018

Epizyme, Inc. , a clinical-stage company developing novel epigenetic therapies, today announced that management will present at the following upcoming investor confer


Research Report Identifies Blucora, Sapiens International Corporation N.V, AxoGen, Epizyme, Nova Measuring Instruments, and Silver Standard Resources with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Posted on Monday August 20, 2018

NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Blucora, ...


Edited Transcript of EPZM earnings conference call or presentation 2-Aug-18 12:30pm GMT
Posted on Sunday August 05, 2018

Q2 2018 Epizyme Inc Earnings Call


Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks
Posted on Friday August 03, 2018

Shares of Epizyme (EPZM) crashed almost 24% following the second quarter earnings release. The company delayed the first ever new drug application filing of its pipeline candidate-tazemetostat by six months.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.